Transaction Case Studies

Global Development and Commercialization Agreement for Novel Cancer Therapeutic

Situation Assessment

  • AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood- brain barrier to treat brain diseases.
  • Lead program, ANG1005, a novel taxane derivative, demonstrated impressive clinical activity in patients with primary and metastatic brain tumors.
  • Engaged Locust Walk Partners as its exclusive commercial and business development advisor.

Key Activities

  • Developed a comprehensive commercial assessment which included conducting primary market research among physicians and payors. Formulated high-impact revenue model that was instrumental in forming partners’ perceptions of overall opportunity and for negotiating deal terms.
  • Led an outreach to a targeted list of leading global and regional companies active in the development and commercialization of oncology products.
  • Led multiple parties through a confidential diligence process leading to competing term sheets.
  • Conducted face-to-face negotiations of the term sheet and definitive agreement.

Successful Outcome

  • Competitive negotiations process resulted in $35M upfront and undisclosed milestones and royalties for an exclusive global partnership for GRN1005 (formerly ANG1005).
  • Transaction also included a multi-year research collaboration for Geron’s proprietary telomerase inhibitor.

View press release »

Back to transactions »


CLIENT: Angiochem


Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase